Current thoughts on the use of methotrexate in patients with psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 2, Issue 1, 1997, Pages 41-46

  Rosenthal, Donald ^a   Guenther, Lyn ^b   Kelly, James ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ROYAL JUBILEE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; ETRETIN; FOLIC ACID; FOLINIC ACID; LIVE VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROBENECID; PROTON PUMP INHIBITOR; RETINOID; SULFONAMIDE;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DRUG CONTRAINDICATION; DRUG COST; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INDIGESTION; LIVER BIOPSY; LIVER PROTECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PSORIASIS; STOMATITIS;

EID: 0031391666     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347549700200111     Document Type: Article

References (44)

1. Dubin DB. Making methotrexate therapy more palatable. Fitzpatrick's J Clin Dermatol 1995; 3:48, 49, 52, 57.
2. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28:466-469.
3. Morgan S, Baggot JE, Vaugan WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994; 121:833-841.
4. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Arthritis Rheum 1993; 36:795-803.
5. Casserly CM, Stange KC, Chren M-M. Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. J Am Acad Dermatol 1993; 29:477-480.
6. Guzzo C. Folic acid supplementation with methotrexate therapy: what benefit if any? [Letter] J Am Acad Dermatol 1994; 31:689.
7. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986; 29:832-835.
8. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988; 31:906-908.
9. Joyce DA, Will RK, Hoffman DM, et al. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991; 50:913-914.
10. Jeffes EWB III, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104:183-188.
11. Cream JJ, Poll DS. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 1980; 102:557-563.
12. Ternowitz T, Bjerring P, Andersen PH, et al. Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis. J Invest Dermatol 1987; 89:192-196.
13. Lammers AM, van de Kerkhof PCM, Mier PD. Reduction of leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes by methotrexate in psoriasis. Br J Dermatol 1987; 116:667-671.
14. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92:2675-2682.
15. Zachariae H, Sogaard H, Heickendorff L. Methotrexate-induced liver cirrhosis. Dermatology 1996; 192:343-346.
16. Zachariae H, Grunnet E, Sogaard H. Liver biopsies in methotrexate-treated psoriatics - a re-evaluation. Acta Derm Venereol (Stockh) 1995; 55:291-296.
17. Berge L, Lundquist A, Rorsman H, Akerman M. Liver biopsy in psoriasis. Br J Dermatol 1970; 82:251-252.
18. Roenigk HH, Bergfeld WF, St. Jacques R, et al. Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 1971; 103:250-261.
19. Weinstein G, Roenigk H, Maibach H, et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108:36-42.
20. Nyfors A, Poulsen H. Liver biopsies from psoriatics related to methotrexate therapy in 88 patients. Acta Pathol Microbiol Scand A 1976; 84:262-270.
21. Ashton RE, Millward-Saddler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982; 79:229-232.
22. Pestana A, Halprin KM, Taylor JR, et al. Predictive value of HLA antigen for methotrexate-induced liver damage in patients with psoriasis. J Am Acad Dermatol 1985; 12:26-29.
23. Dahl MGC, Gregory MM, Scheuer PJ. Liver damage due to methotrexate in patients with psoriasis. BMJ 1971; 1:625-630.
24. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130:204-210.
25. Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 1988; 88:1337-1345.
26. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic abnormalities: a meta-analysis. Am J Med 1991; 90:711-716.
27. Petrazzuoli M, Rothe MJ, Grin-Jorgensen C, et al. Monitoring patients taking methotrexate for hepatotoxicity. J Am Acad Dermatol 1994; 31:969-977.
28. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term MTX treatment - improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125:1218-1224.
29. Zachariae H, Sogaard H. MTX-induced liver cirrhosis. A follow-up. Dermatologica 1987; 175:178-182.
30. Boffa MJ, Chalmers RJG, Haboubi NY, et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133:774-778.
31. Lanse SB, Arnold GL, Gowans JDC. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: an acceptable risk/benefit ratio. Dig Dis Sci 1985; 30:104-109.
32. Gilbert SC, Klintmalm G, Menter A, et al. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. Arch Intern Med 1990; 150:889-891.
33. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19:145-156.
34. Peckham PE, Weinstein GD, McCullogh JL. The treatment of severe psoriasis - a national survey. Arch Dermatol 1987; 123:1303-1307.
35. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37:316-328.
36. Workshop of the research unit of the Royal College of Physicians of London, Department of Dermatology, University of Glasgow; British Association of Dermatologists. BMJ 1996; 303:829-835.
37. Watson RGP, Smallwood RA. Low dose methotrexate therapy and hepatotoxicity. Med J Australia 1991; 155:428-430.
38. Coulson IH, McKenzie J, Neild VS, Joseph AE, Marsden RA. A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long-term methotrexate therapy. Br J Dermatol 1987; 116:491-495.
39. Zachariae H, Aslam HM, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25:50-53.
40. O'Connor GT, Olmstead EM, Zug K, et al. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis. Arch Dermatol 1989; 125:1209-1217.
41. Bergquist SR, Felson DT, Freedberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients on methotrexate [Abstr]. Arthritis Rheum 1993; 36(Suppl 5):R32.
42. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2:165-173.
43. Garcia-Tsao G. Outpatient liver biopsy: how safe is it? Ann Int Med 1993;118:150-153.
44. Evaluation of drug interactions. First DataBank, The Hurst Corporation, 1995. Hansten and Horn's: Drug interactions analysis and management. Applied Therapeutics, Inc., 1997. Micromedex Inc. Computerized database, 1997.